JP2009539828A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009539828A5 JP2009539828A5 JP2009514228A JP2009514228A JP2009539828A5 JP 2009539828 A5 JP2009539828 A5 JP 2009539828A5 JP 2009514228 A JP2009514228 A JP 2009514228A JP 2009514228 A JP2009514228 A JP 2009514228A JP 2009539828 A5 JP2009539828 A5 JP 2009539828A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- alkyl
- compound according
- thioxanthine
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 4
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- SOUGGMGRCJZECV-UHFFFAOYSA-N 3-(2-ethoxy-2-methylpropyl)-2-sulfanylidene-7h-purin-6-one Chemical compound O=C1NC(=S)N(CC(C)(C)OCC)C2=C1NC=N2 SOUGGMGRCJZECV-UHFFFAOYSA-N 0.000 claims 1
- QOTIDWBGIWZLOV-UHFFFAOYSA-N 3-(2-ethoxypropyl)-2-sulfanylidene-7h-purin-6-one Chemical compound O=C1NC(=S)N(CC(C)OCC)C2=C1NC=N2 QOTIDWBGIWZLOV-UHFFFAOYSA-N 0.000 claims 1
- HPGLYLFGBHDESB-UHFFFAOYSA-N 3-(2-methoxy-2-methylpropyl)-2-sulfanylidene-7h-purin-6-one Chemical compound O=C1NC(=S)N(CC(C)(C)OC)C2=C1NC=N2 HPGLYLFGBHDESB-UHFFFAOYSA-N 0.000 claims 1
- HHCAUZJXLFBINI-UHFFFAOYSA-N 3-(2-methyl-2-propoxypropyl)-2-sulfanylidene-7h-purin-6-one Chemical compound O=C1NC(=S)N(CC(C)(C)OCCC)C2=C1NC=N2 HHCAUZJXLFBINI-UHFFFAOYSA-N 0.000 claims 1
- SGEATRKRHOYVDE-UHFFFAOYSA-N 3-(2-propan-2-yloxyethyl)-2-sulfanylidene-7h-purin-6-one Chemical compound O=C1NC(=S)N(CCOC(C)C)C2=C1NC=N2 SGEATRKRHOYVDE-UHFFFAOYSA-N 0.000 claims 1
- QOTIDWBGIWZLOV-ZCFIWIBFSA-N 3-[(2r)-2-ethoxypropyl]-2-sulfanylidene-7h-purin-6-one Chemical compound O=C1NC(=S)N(C[C@@H](C)OCC)C2=C1NC=N2 QOTIDWBGIWZLOV-ZCFIWIBFSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 206010065563 Eosinophilic bronchitis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 0 *N(c1c(C(N2)=O)[n]cn1)C2=S Chemical compound *N(c1c(C(N2)=O)[n]cn1)C2=S 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81091906P | 2006-06-05 | 2006-06-05 | |
| PCT/SE2007/000537 WO2007142576A1 (en) | 2006-06-05 | 2007-06-04 | 2-thioxanthine derivatives acting as mpo-inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009539828A JP2009539828A (ja) | 2009-11-19 |
| JP2009539828A5 true JP2009539828A5 (enExample) | 2010-07-22 |
Family
ID=38801720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009514228A Pending JP2009539828A (ja) | 2006-06-05 | 2007-06-04 | Ｍｐｏ阻害剤として作用する２−チオキサンチン誘導体 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7943625B2 (enExample) |
| EP (1) | EP2029598A4 (enExample) |
| JP (1) | JP2009539828A (enExample) |
| KR (1) | KR20090014189A (enExample) |
| CN (1) | CN101460498A (enExample) |
| AR (1) | AR061134A1 (enExample) |
| AU (1) | AU2007256005B2 (enExample) |
| BR (1) | BRPI0712310A2 (enExample) |
| CA (1) | CA2653774A1 (enExample) |
| CL (1) | CL2007001590A1 (enExample) |
| EC (1) | ECSP088965A (enExample) |
| IL (1) | IL195287A0 (enExample) |
| MX (1) | MX2008014991A (enExample) |
| NO (1) | NO20085269L (enExample) |
| RU (1) | RU2435772C2 (enExample) |
| TW (1) | TW200804383A (enExample) |
| UA (1) | UA94606C2 (enExample) |
| UY (1) | UY30387A1 (enExample) |
| WO (1) | WO2007142576A1 (enExample) |
| ZA (1) | ZA200809800B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
| SE0302756D0 (sv) * | 2003-10-17 | 2003-10-17 | Astrazeneca Ab | Novel Compounds |
| MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| TW200806667A (en) * | 2006-04-13 | 2008-02-01 | Astrazeneca Ab | New compounds |
| TW200804383A (en) * | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
| US20090053176A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Combination 937 |
| US20110144049A1 (en) * | 2009-10-21 | 2011-06-16 | Serebruany Victor L | Treating Cardiac Arrhythmias, Heart Failure, Peripheral Artery Disease and Stroke with Cyclopentyl-Triazolo-Pyrimidine or Derivative Thereof |
| US8765126B2 (en) * | 2011-05-05 | 2014-07-01 | Robert Sackstein | Methods of treating complications and disorders associated with G-CSF administration |
| BR112014011254A2 (pt) * | 2011-11-11 | 2017-05-16 | Pfizer | 2-tiopirimidinonas |
| US9221821B2 (en) | 2012-06-05 | 2015-12-29 | Forest Laboratories Holdings, Limited | Methods for the synthesis of 1,3-substituted aminouracils and other xanthine-related compounds |
| WO2015134210A1 (en) | 2014-03-03 | 2015-09-11 | Principia Biopharma, Inc. | BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS |
| WO2015196245A1 (en) * | 2014-06-25 | 2015-12-30 | Adelaide Research & Innovation Pty Ltd | Modulation of osteogenesis and or angiogenesis by modulating peroxidase functionality |
| US9616063B2 (en) | 2014-12-01 | 2017-04-11 | Astrazeneca Ab | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase |
| CR20170498A (es) | 2015-05-05 | 2018-01-26 | Pfizer | 2-tiopirimidinonas |
| EP3298011B1 (en) | 2015-05-22 | 2021-11-17 | Principia Biopharma Inc. | Quinolone derivatives as fibroblast growth factor receptor inhibitors |
| HRP20211249T1 (hr) | 2015-06-03 | 2021-11-12 | Principia Biopharma Inc. | Inhibitori tirozin kinaze |
| JP2025528217A (ja) | 2022-08-18 | 2025-08-26 | アストラゼネカ・アクチエボラーグ | ミエロペルオキシダーゼの阻害剤 |
| EP4624473A1 (en) * | 2022-12-09 | 2025-10-01 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Pyrrolo[3,2-d]pyrimidin-4-one derivative, and preparation method therefor and medical use thereof |
| WO2025172474A1 (en) | 2024-02-15 | 2025-08-21 | Astrazeneca Ab | Inhibitors of myeloperoxidase |
| WO2025190901A1 (en) | 2024-03-13 | 2025-09-18 | Institut National de la Santé et de la Recherche Médicale | Use of myeloperoxidase (mpo) inhibitors for promoting cd8+ t cell responses |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3135753A (en) | 1961-05-10 | 1964-06-02 | Burroughs Wellcome Co | Alkylthiopurines and method |
| SE7810947L (sv) | 1978-10-20 | 1980-04-21 | Draco Ab | 3-alkylxanthines |
| GB8418430D0 (en) * | 1984-07-19 | 1984-08-22 | Beecham Wuelfing Gmbh & Co Kg | Treatment |
| US4710503A (en) | 1985-02-07 | 1987-12-01 | Euroceltique S.A. | 6-thioxanthine derivatives |
| WO1989006125A1 (en) | 1987-12-31 | 1989-07-13 | Smithkline Beckman Corporation | 4-aralkyl-5-substituted-1,2,4-triazole-5-thiols |
| DK440989A (da) | 1988-09-12 | 1990-03-13 | Smithkline Beecham Corp | Dopamin-beta-hydroxylase inhibitorer |
| JPH02160235A (ja) | 1988-12-13 | 1990-06-20 | Konica Corp | ハロゲン化銀カラー写真画像の形成方法 |
| AU5436790A (en) * | 1989-04-19 | 1990-11-16 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Sulfer-containing xanthine derivatives as adenosin antagonists |
| EP0430300A3 (en) | 1989-12-01 | 1992-03-25 | Takeda Chemical Industries, Ltd. | Xanthine derivatives, their production and use |
| US5100906A (en) | 1990-04-19 | 1992-03-31 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-4-alkyl-3h-1,2,4-triazole-3-thiones useful as memory enhancers |
| FR2665636B1 (fr) | 1990-08-10 | 1994-10-07 | Adir | Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer. |
| US6046019A (en) | 1991-07-09 | 2000-04-04 | Goumeniouk; Alexander P. | Diagnostic kits and methods for making granulocyte cell counts |
| US6469017B1 (en) | 1998-01-16 | 2002-10-22 | Cell Therapeutics, Inc. | Method of inhibiting interleukin-12 signaling |
| GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
| NZ274244A (en) | 1993-11-26 | 1997-09-22 | Pfizer | Isoxazoline derivatives and medicaments |
| US5489598A (en) | 1994-06-08 | 1996-02-06 | Warner-Lambert Company | Cytoprotection utilizing aryltriazol-3-thiones |
| US6025361A (en) | 1994-12-13 | 2000-02-15 | Euro-Celtique, S.A. | Trisubstituted thioxanthines |
| CA2206287C (en) | 1994-12-13 | 2001-03-20 | Mark Chasin | Aryl thioxanthines |
| WO1996018400A1 (en) | 1994-12-13 | 1996-06-20 | Euro-Celtique, S.A. | Trisubstituted thioxanthines |
| US5756511A (en) | 1995-04-03 | 1998-05-26 | Cell Therapeutics, Inc. | Method for treating symptoms of a neurodegenerative condition |
| US6294541B1 (en) | 1996-06-06 | 2001-09-25 | Euro-Celtique S.A. | Purine derivatives having phosphodiesterase IV inhibition activity |
| DE19707655A1 (de) * | 1997-02-26 | 1998-08-27 | Hoechst Ag | Kombinationspräparat zur Anwendung bei Demenz |
| US5976823A (en) | 1997-03-19 | 1999-11-02 | Integrated Biomedical Technology, Inc. | Low range total available chlorine test strip |
| ES2264210T3 (es) | 1997-09-05 | 2006-12-16 | Kyowa Hakko Kogyo Co., Ltd. | Derivados de xantina para el tratamiento de la isquemia cerebral. |
| AU9297798A (en) | 1997-09-16 | 1999-04-05 | G.D. Searle & Co. | Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity |
| AR013669A1 (es) | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| US6319928B1 (en) | 1998-11-30 | 2001-11-20 | Euro-Celtique, S.A. | Purine derivatives having phosphodiesterase IV inhibition activity |
| DZ3019A1 (fr) | 1999-03-01 | 2005-05-20 | Smithkline Beecham Corp | Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd. |
| WO2000059449A2 (en) | 1999-04-02 | 2000-10-12 | Euro-Celtique S.A. | Purine derivatives having phosphodiesterase iv inhibition activity |
| GB2362101A (en) | 2000-05-12 | 2001-11-14 | Astrazeneca Ab | Treatment of chronic obstructive pulmonary disease |
| FR2811989A1 (fr) | 2000-07-18 | 2002-01-25 | Sanofi Synthelabo | Derives de polyfluoroalkytriazole, leur preparation et leur application en therapeutique |
| EP1305328A2 (en) | 2000-07-21 | 2003-05-02 | Mark B. Lyles | Materials and methods for binding nucleic acids to surfaces |
| FR2819723B1 (fr) | 2001-01-23 | 2006-11-17 | Arnaud Mainnemare | Composition halogene, son procede de preparation et ses utilisations |
| WO2002066447A1 (en) | 2001-02-21 | 2002-08-29 | Ono Pharmaceutical Co., Ltd. | 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors |
| WO2002090575A1 (en) | 2001-05-08 | 2002-11-14 | Astrazeneca Ab | An assay for detecting inhibitors of the enzyme mueloperokidase |
| SE0103766D0 (sv) | 2001-11-09 | 2001-11-09 | Astrazeneca Ab | Novel assay |
| ES2193839B1 (es) | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
| ES2208063B1 (es) | 2002-04-01 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida. |
| AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
| RU2223273C1 (ru) * | 2002-08-16 | 2004-02-10 | Давлетьярова Альпия Васильевна | Производные 1,3-диметил-8-(2-гидроксипропил-1) тиоксантина, проявляющие биологическую активность |
| SE0301232D0 (sv) | 2003-04-25 | 2003-04-25 | Astrazeneca Ab | Novel use |
| SE0302756D0 (sv) * | 2003-10-17 | 2003-10-17 | Astrazeneca Ab | Novel Compounds |
| WO2005042534A2 (en) | 2003-10-31 | 2005-05-12 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists |
| SI1781657T1 (sl) | 2004-02-14 | 2013-07-31 | Glaxosmithkline Intellectual Property Development Limited | Zdravila z aktivnostjo na receptor hm74a |
| WO2006045564A1 (en) | 2004-10-22 | 2006-05-04 | Smithkline Beecham Corporation | Xanthine derivatives with hm74a receptor activity |
| SE0402591D0 (sv) | 2004-10-25 | 2004-10-25 | Astrazeneca Ab | Novel use |
| MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| TW200806667A (en) * | 2006-04-13 | 2008-02-01 | Astrazeneca Ab | New compounds |
| TW200804383A (en) * | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
| US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
-
2007
- 2007-05-30 TW TW096119344A patent/TW200804383A/zh unknown
- 2007-05-31 AR ARP070102350A patent/AR061134A1/es not_active Application Discontinuation
- 2007-06-01 CL CL2007001590A patent/CL2007001590A1/es unknown
- 2007-06-01 US US11/756,967 patent/US7943625B2/en not_active Expired - Fee Related
- 2007-06-04 CA CA002653774A patent/CA2653774A1/en not_active Abandoned
- 2007-06-04 BR BRPI0712310-8A patent/BRPI0712310A2/pt not_active IP Right Cessation
- 2007-06-04 UA UAA200813045A patent/UA94606C2/ru unknown
- 2007-06-04 MX MX2008014991A patent/MX2008014991A/es active IP Right Grant
- 2007-06-04 KR KR1020087029646A patent/KR20090014189A/ko not_active Withdrawn
- 2007-06-04 RU RU2008145971/04A patent/RU2435772C2/ru not_active IP Right Cessation
- 2007-06-04 JP JP2009514228A patent/JP2009539828A/ja active Pending
- 2007-06-04 UY UY30387A patent/UY30387A1/es unknown
- 2007-06-04 WO PCT/SE2007/000537 patent/WO2007142576A1/en not_active Ceased
- 2007-06-04 US US12/300,673 patent/US20090131459A1/en not_active Abandoned
- 2007-06-04 EP EP07748200A patent/EP2029598A4/en not_active Withdrawn
- 2007-06-04 CN CNA2007800209903A patent/CN101460498A/zh active Pending
- 2007-06-04 AU AU2007256005A patent/AU2007256005B2/en not_active Ceased
-
2008
- 2008-11-13 IL IL195287A patent/IL195287A0/en unknown
- 2008-11-17 ZA ZA200809800A patent/ZA200809800B/xx unknown
- 2008-12-12 EC EC2008008965A patent/ECSP088965A/es unknown
- 2008-12-16 NO NO20085269A patent/NO20085269L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009539828A5 (enExample) | ||
| RU2008145971A (ru) | Производные 2-тиоксантина, действующие в качестве ингибиторов мро | |
| JP2007518738A5 (enExample) | ||
| JP2010511626A5 (enExample) | ||
| JP2009530399A5 (enExample) | ||
| JP2008543860A5 (enExample) | ||
| JP2014500861A5 (enExample) | ||
| JP2011057693A5 (enExample) | ||
| JP2006143751A5 (enExample) | ||
| JP2005508349A5 (enExample) | ||
| JP2010501584A5 (enExample) | ||
| JP2018518537A5 (enExample) | ||
| JP2010532768A5 (enExample) | ||
| JP2009535462A5 (enExample) | ||
| JP2010526777A5 (enExample) | ||
| JP2015521167A5 (enExample) | ||
| JP2009501198A5 (enExample) | ||
| JP2008540554A5 (enExample) | ||
| JP2012530758A5 (enExample) | ||
| JP2008539268A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2013514980A5 (enExample) | ||
| RU2007146669A (ru) | Пролекарства антагонистов a2b рецептора аденозина | |
| JP2015520738A5 (enExample) | ||
| JP2010510232A5 (enExample) |